PAUL A. MAHON - 21 Mar 2024 Form 4 Insider Report for UNITED THERAPEUTICS Corp (UTHR)

Role
EVP & GENERAL COUNSEL
Signature
/s/ John S. Hess, Jr. under Power of Attorney
Issuer symbol
UTHR
Transactions as of
21 Mar 2024
Transactions value $
-$712,166
Form type
4
Filing time
22 Mar 2024, 16:30:35 UTC
Previous filing
07 Mar 2024
Next filing
04 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction UTHR Common Stock Options Exercise $706,560 +6,000 +16% $117.76 42,710 21 Mar 2024 Direct F1, F2
transaction UTHR Common Stock Sale -$200,634 -857 -2% $234.11 41,853 21 Mar 2024 Direct F1, F3
transaction UTHR Common Stock Sale -$56,104 -238 -0.57% $235.73 41,615 21 Mar 2024 Direct F1, F4
transaction UTHR Common Stock Sale -$829,683 -3,505 -8.4% $236.71 38,110 21 Mar 2024 Direct F1, F5
transaction UTHR Common Stock Sale -$332,304 -1,400 -3.7% $237.36 36,710 21 Mar 2024 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction UTHR Stock Options Options Exercise $0 -6,000 -10% $0 54,000 21 Mar 2024 Common Stock 6,000 $117.76 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
F2 Includes 118 shares acquired on March 4, 2024, under the United Therapeutics Corporation Employee Stock Purchase Plan.
F3 This transaction was executed in multiple trades at prices ranging from $233.74 to $234.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $235.16 to $236.15. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $236.20 to $237.195. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $237.22 to $237.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.